Category Archives: Ulcerative Colitis

My Journey= Ulcerative Colitis Proctitis PART#2 Hi My name is Ghiselle and I was recently diagnosed with Ulcerative Colitis Proctitis. I will be making these videos to talk about my symptoms and updates wi... By: My Journey Living with UC … Continue reading →

PUBLIC RELEASE DATE: 23-Oct-2014 Contact: Dr. Anna-Sabine Ernst presse@iqwig.de 49-022-135-6850 Institute for Quality and Efficiency in Health Care Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether the drug offers an added benefit over the appropriate comparator therapy in these patient groups. According to the findings, such an added benefit is not proven because the dossier contained no suitable data for any of the two therapeutic indications. G-BA specified adalimumab or infliximab as comparator therapy Crohn disease and ulcerative colitis are chronic inflammatory bowel diseases. Vedolizumab is an option when conventional therapy is not tolerated or does not provide sufficient release of symptoms. This conventional treatment can also be a tumour necrosis factor alpha (TNF) antagonist. The Federal Joint Committee (G-BA) specified a TNF antagonist (adalimumab or infliximab) as appropriate comparator therapy for both therapeutic indications. It is to be noted that it is possible to switch to a different TNF antagonist or to adjust … Continue reading →

My Journey= Ulcerative Colitis Proctitis PART#3 Hi My name is Ghiselle and I was recently diagnosed with Ulcerative Colitis Proctitis. I will be making these videos to talk about my symptoms and updates wi... By: My Journey Living with UC … Continue reading →

PUBLIC RELEASE DATE: 21-Oct-2014 Contact: Rachel Steigerwald media@gastro.org 301-272-1603 American Gastroenterological Association @AmerGastroAssn Bethesda, MD (Oct. 21, 2014) If you are not getting the recommended seven-to-eight hours of sleep each night, you may be at increased risk of developing ulcerative colitis, according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. "Both short and long durations of sleep have important health implications and are associated with increased overall mortality, cardiovascular disease and cancer," said lead study author Ashwin N. Ananthakrishnan, MD, MPH, Massachusetts General Hospital. "Our findings indicate that ulcerative colitis may potentially be added to this list. We found that less than six hours of sleep per day and more than nine hours of sleep per day are each associated with an increased risk of ulcerative colitis." Researchers conducted a prospective study of women who were enrolled in the Nurses' Health Study (NHS) I since 1976 and NHS II since 1989 and followed through detailed biennial questionnaires with greater than 90 percent follow-up. The large size of the cohorts, prospective design and prolonged duration of follow-up provide a unique opportunity to examine the association between sleep duration and incident … Continue reading →

SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today that its CORTIMENT MMX (budesonide) treatment for the induction of remission in patients with active, mild to moderate ulcerative colitis1 has received marketing approval from 27 European Union member states2 following the EU Mutual Recognition Procedure. CORTIMENT has been commercially available in the Netherlands since November 2013. Ferring plans to begin launching the product in the 27 additional European countries in the coming months. CORTIMENT contains budesonide, a locally acting glucocorticosteroid, in a novel oral tablet formulation utilizing MMX multimatrix colonic delivery technology. The approved dosing regimen for adult patients is one 9 mg tablet taken once daily for up to 8 weeks. In phase III studies, 2.4 to 3.9 times more patients achieved clinical and endoscopic remission with CORTIMENT compared to placebo, and no clinically significant glucocorticosteroid side effects were seen versus placebo after eight weeks of treatment (CORE I study and CORE II study respectively). 3 CORTIMENT has been developed by Cosmo Pharmaceuticals SpA. Ferring is the licensee in the EU and Asia (excluding Japan), Australia, Canada, Latin America and Africa. In the United States, where the product is available as UCERIS, the licensee is Salix Pharmaceuticals, Inc. Dr. Simon Travis, … Continue reading →

Ulcerative Colitis Me Just for fun supporting #getyourbellyout. By: Gary Anderson … Continue reading →

Take Steps Walk for Crohn's and Colitis Crohn's disease and ulcerative colitis affects nearly 1 in 200 Americans, with 70000 new cases in the U.S. each year. By: WWLP-22News … Continue reading →

Taylor Healing process Taylor was only 22 when he went into the hospital for Ulcerative Colitis. After many doses of steroids , remicade and dilaudid nothing helped to bring the inflamation down. A total colostomy... By: Play Don't Worry … Continue reading →

Treating Pediatric Inflammatory Bowel Disease Twenty-five percent of Inflammatory Bowel Disease cases are diagnosed in the pediatric population. Crohn's disease and ulcerative colitis have a lasting impact on a young person's development... By: University of Pittsburgh Medical Center … Continue reading →

Depression Stress Anxiety IBS Colitis Arthritis Treatment Allergy Testing Reiki Healing Scotland W Helping you to heal... naturally! http://www.eugenieyoung.com Ulcerative Colitis is one disease that I have experienced phenomenal success treating. People have, in a short period of time,... By: Eugenie Young … Continue reading →